IP Library › Granted Patent US 12,444,477
Granted Patent B2
US 12,444,477 · App. 17/095,970 · Granted Oct 14, 2025

Antibody selection apparatus and methods

Inventors: Vikas K. Sharma (Millbrae, CA); Trevor E. Swartz (San Carlos, CA); Thomas W. Patapoff (San Carlos, CA)
Assignee: GENENTECH, INC.
G16B15/00C07K16/00G01N33/531G16B35/00G16B35/20G16C20/60C07K2317/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,444,477
App. No.
17/095,970
Granted
Oct 14, 2025
Kind
B2
Abstract

Apparatus, systems, computer-readable media, articles of manufacture and methods for selecting an antibody. Apparatus, systems, computer-readable media, articles of manufacture and methods for producing the selected antibody. The selecting may include determining one or more physiochemical characteristics of the antibody. The determining may be based on antibody structural parameters.

Claims (89)

1. A computer-implemented method comprising:

obtaining a clearance rate criterion for an antibody;

calculating a net charge using a light chain variable domain (VL) amino acid sequence and a heavy chain variable domain (VH) amino acid sequence of the antibody;

determining the net charge is within a specific net charge range;

calculating, using a molecular dynamics (MD) simulation, a hydrophobicity from one or more complementarity determining regions (CDRs) of the antibody;

determining the hydrophobicity is within a hydrophobicity range;

determining that the antibody has a predicted clearance rate that is below or equal to the clearance rate criterion;

determining that the antibody is suitable for inclusion in a pharmaceutical product; and

manufacturing the antibody and/or the pharmaceutical product comprising the antibody, wherein the manufactured antibody comprises: (i) the net charge being within the specific net charge range, (ii) the hydrophobicity being within the hydrophobicity range, and (iii) the predicted clearance rate being below or equal to the clearance rate criterion.

2. The method of claim 1 , wherein the net charge comprises a sum of a net charge of the VL amino acid sequence and a net charge of the VH amino acid sequence.

3. The method of claim 1 , wherein the net charge comprises a sum of a net charge of the VL amino acid sequence and a net charge of the VH amino acid sequence, at about pH 5.5.

4. The method of claim 1 , wherein the hydrophobicity comprises a total of summation functions of values of hydrophobicity of the one or more CDRs.

5. The method of claim 4 , wherein each of the summation functions is a ratio of a sum of values of hydrophobic residues of a CDR and of a sum of values of hydrophilic residues of the CDR.

6. The method of claim 5 , wherein the values are Eisenberg hydrophobicity scale values.

7. The method of claim 5 , wherein the one or more CDRs comprise one, two, three, four, five or six CDRs.

8. The method of claim 5 , wherein the one or more CDRs comprise all six CDRs.

9. The method of claim 5 , wherein the one or more CDRs are light chain (LC) CDR1, LC CDR3 and heavy chain (HC) CDR3.

10. The method of claim 1 , wherein the clearance rate criterion is no more than about 10 mL/kg/day measured in a cynomolgus monkey model.

11. The method of claim 1 , wherein the specific net charge range is from about −2.0 to about 6.2, and wherein an upper limit of the hydrophobicity range is about 4.

12. The method of claim 1 , wherein the antibody is a monoclonal antibody.

13. The method of claim 12 , wherein the antibody is an IgG1 antibody.

14. The method of claim 1 , wherein the antibody is a therapeutic antibody.

15. The method of claim 1 , further comprising:

obtaining for the antibody:

a first scaling factor that corresponds to the net charge, and

a second scaling factor that corresponds to the hydrophobicity; and

determining the predicted clearance rate for the antibody using an objective function comprising the first scaling factor, the second scaling factor, the net charge, and the hydrophobicity.

16. The method of claim 15 , further comprising:

receiving a set of data, the set of data comprising (i) information pertaining to the antibody, the information includes the VL amino acid sequence and the VH amino acid sequence, (ii) conditions of a solution comprising the antibody, and (iii) one or more physiochemical characteristics to be evaluated, the one or more physiochemical characteristics include clearance rate;

determining a design criterion based on the set of data, the design criterion including the clearance rate criterion for the antibody;

selecting the objective function based on the set of data and the design criterion;

selecting parameters to be included in the objective function based on the set of data, the parameters including the net charge and the hydrophobicity of the antibody;

selecting scaling factors to be included in the objective function based on the set of data and the parameters, the scaling factors including the first scaling factor and the second scaling factor;

calculating values for the parameters based on the set of data;

retrieving values for the scaling factors from a memory store; and

determining the predicted clearance rate of the antibody using the objective function including the values for the parameters and the values for the scaling factors.

17. The method of claim 16 , wherein the antibody prior to manufacturing is a virtual antibody and the solution is a virtual solution.

18. The method of claim 17 , wherein the antibody is manufactured according to a method of culturing, under conditions suitable for expressing the antibody, a host cell comprising nucleic acid encoding the antibody.

19. A system comprising:

a manufacturing vessel;

one or more data processors; and

a non-transitory computer readable storage medium containing instructions which, when executed on the one or more data processors, cause the one or more data processors to perform actions including:

obtaining a clearance rate criterion for an antibody;

calculating a net charge using a light chain variable domain (VL) amino acid sequence and a heavy chain variable domain (VH) amino acid sequence of the antibody;

determining the net charge is within a specific net charge range;

in response to the determination that the net charge is within the specific net charge range, calculating, using a molecular dynamics (MD) simulation, a hydrophobicity from one or more complementarity determining regions (CDRs) of the antibody;

determining the hydrophobicity is within a hydrophobicity range;

in response to the determination that the hydrophobicity is within the hydrophobicity range, determining that the antibody has a predicted clearance rate below or equal to the clearance rate criterion and determining that the antibody is suitable for inclusion in a pharmaceutical product;

in response to the determination that the antibody is suitable for inclusion in a pharmaceutical product, providing an amino acid sequence of the antibody and/or structural information of the antibody for manufacturing the antibody and/or the pharmaceutical product comprising the antibody; and

prompting the manufacturing vessel to manufacture the antibody and/or the pharmaceutical product based on the amino acid sequence of the antibody and/or the structural information of the antibody.

20. The system of claim 19 , wherein the actions further comprise:

obtaining for the antibody:

a first scaling factor that corresponds to the net charge, and

a second scaling factor that corresponds to the hydrophobicity; and

determining the predicted clearance rate for the antibody using an objective function comprising the first scaling factor, the second scaling factor, the net charge, and the hydrophobicity.

21. The system of claim 20 , wherein the actions further comprise:

receiving a set of data, the set of data comprising (i) information pertaining to the antibody, the information includes the VL amino acid sequence and the VH amino acid sequence, (ii) conditions of a solution comprising the antibody, and (iii) one or more physiochemical characteristics to be evaluated, the one or more physiochemical characteristics include clearance rate;

determining a design criterion based on the set of data, the design criterion including the clearance rate criterion for the antibody;

selecting the objective function based on the set of data and the design criterion;

selecting parameters to be included in the objective function based on the set of data, the parameters including the net charge and the hydrophobicity of the antibody;

selecting scaling factors to be included in the objective function based on the set of data and the parameters, the scaling factors including the first scaling factor and the second scaling factor;

calculating values for the parameters based on the set of data;

retrieving values for the scaling factors from a memory store; and

determining the predicted clearance rate of the antibody using the objective function including the values for the parameters and the values for the scaling factors.

22. The system of claim 21 , wherein the antibody prior to manufacturing is a virtual antibody and the solution is a virtual solution.

23. A computer-program product tangibly embodied in a non-transitory machine-readable storage medium, including instructions configured to cause one or more data processors coupled to a manufacturing vessel to perform actions including:

obtaining a clearance rate criterion for an antibody;

calculating a net charge using a light chain variable domain (VL) amino acid sequence and a heavy chain variable domain (VH) amino acid sequence of the antibody;

determining the net charge is within a specific net charge range;

in response to the determination that the net charge is within the specific net charge range, calculating, using a molecular dynamics (MD) simulation, a hydrophobicity from one or more complementarity determining regions (CDRs) of the antibody;

determining the hydrophobicity is within a hydrophobicity range;

in response to the determination that the hydrophobicity is within the hydrophobicity range, determining that the antibody has a predicted clearance rate below or equal to the clearance rate criterion and determining that the antibody is suitable for inclusion in a pharmaceutical product;

in response to the determination that the antibody is suitable for inclusion in a pharmaceutical product, communicating with the manufacturing vessel to provide an amino acid sequence of the antibody and/or structural information of the antibody for manufacturing the antibody and/or the pharmaceutical product comprising the antibody; and

causing the manufacturing vessel to manufacture the antibody.

24. The computer-program product of claim 23 , wherein the actions further comprise:

obtaining for the antibody:

a first scaling factor that corresponds to the net charge, and

a second scaling factor that corresponds to the hydrophobicity; and

determining the predicted clearance rate for the antibody using an objective function comprising the first scaling factor, the second scaling factor, the net charge, and the hydrophobicity.

25. The computer-program product of claim 24 , wherein the actions further comprise:

receiving a set of data, the set of data comprising (i) information pertaining to the antibody, the information includes the VL amino acid sequence and the VH amino acid sequence, (ii) conditions of a solution comprising the antibody, and (iii) one or more physiochemical characteristics to be evaluated, the one or more physiochemical characteristics include clearance rate;

determining a design criterion based on the set of data, the design criterion including the clearance rate criterion for the antibody;

selecting the objective function based on the set of data and the design criterion;

selecting parameters to be included in the objective function based on the set of data, the parameters including the net charge and the hydrophobicity of the antibody;

selecting scaling factors to be included in the objective function based on the set of data and the parameters, the scaling factors including the first scaling factor and the second scaling factor;

calculating values for the parameters based on the set of data;

retrieving values for the scaling factors from a memory store; and

determining the predicted clearance rate of the antibody using the objective function including the values for the parameters and the values for the scaling factors.

26. The computer-program product of claim 25 , wherein the antibody prior to manufacturing is a virtual antibody and the solution is a virtual solution.

Continuity (4)
Continuation 15166939 · May 27, 2016
Continuation PCTUS2014067580 · Nov 26, 2014
Provisional Application 61910200 · Nov 29, 2013
Related Publication 20210065843A1 · Mar 4, 2021
References Cited (88)
US 6172213B1 · Lowman et al. · 2001 [cited by applicant]
US 10861584B2 · Sharma et al. · 2020 [cited by applicant]
US 20160132634A1 · Trout et al. · 2016 [cited by applicant]
BR 1120160098625 · 2015 [cited by applicant]
CA 2924448 · 2015 [cited by applicant]
EP 2006381 · 2008 [cited by applicant]
EP 2196541 · 2010 [cited by applicant]
JP 2017512750 · 2017 [cited by applicant]
JP 2020090504 · 2020 [cited by applicant]
KR 1020160088318 · 2016 [cited by applicant]
MX 385775 · 2015 [cited by applicant]
WO 2004039337 · 2004 [cited by applicant]
WO 2007114319A1 · 2007 [cited by applicant]
WO 2009041643A1 · 2009 [cited by applicant]
WO WO2013177470A1 · 2013 [cited by examiner]
WO 2014186692 · 2014 [cited by applicant]
WO 2015081176A3 · 2015 [cited by applicant]
Chames, Patrick, et al. “Therapeutic antibodies: successes, limitations and hopes for the future.” British journal of pharmacology 157.2 (2009): 220-233. (Year: 2009). [cited by examiner]
Conley, Greg P., et al. “Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability.” Biotechnology and bioengineering 108.11 (2011): 2634-2644. (Year: 2011). [cited by examiner]
Boswell, C. Andrew, et al. “Effects of charge on antibody tissue distribution and pharmacokinetics.” Bioconjugate chemistry 21.12 (2010): 2153-2163. (Year: 2010). [cited by examiner]
Sommerfeld, Sven, and Jochen Strube. “Challenges in biotechnology production—generic processes and process optimization for monoclonal antibodies.” Chemical Engineering and Processing: Process Intensification 44.10 (200… [cited by examiner]
Hötzel, Isidro, et al. “A strategy for risk mitigation of antibodies with fast clearance.” MAbs. vol. 4. No. 6. Taylor & Francis, 2012. (Year: 2012). [cited by examiner]
Yadav, Sandeep, et al. “The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions.” Molecular pharmaceutics 9.4 (2012): 791-802. (Year: 2012). [cited by examiner]
Tiwari, Manish Kumar, et al. “Computational approaches for rational design of proteins with novel functionalities.” Computational and structural biotechnology journal 2.3 (2012): e201204002. (Year: 2012). [cited by examiner]
Eisenberg, et al., Hydrophobicity and Amphiphilicity in Protein Structure, Journal of Cellular Biochemistry 31:11-17 (1986), Protein Structure, Folding, and Design 155-161. [cited by applicant]
Wimley, et al., Experimentally Determined Hydrophobicity Scale for Proteins at Membrane Interfaces, Nature Structural Biology, vol. 3, No. 10, Oct. 1996, pp. 842-848. [cited by applicant]
Wimley, et al., Solvation Energies of Amino Acid Side Chains and Backbone in a Family of Host-Guest Pentapeptides, Biochemistry 1996, 35, 5109-5124. [cited by applicant]
Vikas K. Sharma, “Predictive Tooks Towards Screening Monoclonal Antibodies with Optimal Physicochemical Properties”, American Chemical Society, Denver, CO, 22 slides (2011). [cited by applicant]
Kanai, et al., “Rheological properties of high concentration therapeutic antibody solutions” Abstract 232 [cited by applicant]
Laurer, et al., J Pharm Sci., 101:102-115, 2012. [cited by applicant]
Yadav et al., Pharm Res (2011) 28:1750-1764. [cited by applicant]
Bailey, “The CCP4 Suite: Programs for Protein Crystallography” Acta Cryst. 50:760-763 (1994). [cited by applicant]
Bas et al., “Very Fast prediction and rationalization of pKa values for protein-ligand complexes” Proteins 73:765-783 ( 2008). [cited by applicant]
Berendsen et al., “Molecular dynamics with coupling to an external bath” J. Chem. Phys. 81(8):3684-3690 (Oct. 15, 1984). [cited by applicant]
Boswell et al., “Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics” Bioconjugate Chem. 21:2153-2163 ( 2010). [cited by applicant]
Bumbaca et al., “Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics” The AAPS Journal 14(3):554-558 (Sep. 2012). [cited by applicant]
Bussi et al., “Canonical sampling through velocity rescaling” The Journal of Chemical Physics 126:014101-014101-7 ( 2007). [cited by applicant]
Cacia et al., “Isomerization of an Aspartic Acid Residue in the Complementarity-Determining Regions of a Recombinant Antibody to Human IgE: Identification and Effect on Binding Affinity” Biochemistry 35:1897-1903 ( 1996… [cited by applicant]
Chaudhri et al., “The Role of Amino Acid Sequence in the Self-Association of Therapeutic Monoclonal Antibodies: Insights from Coarse-Grained Modeling” The Journal of Physical Chemistry B 117(5):1269-1279 (Feb. 7, 2013). [cited by applicant]
Chennamsetty et al., “Design of Therapeutic proteins with enhanced stability” PNAS 106(29):11937-11942 (Jul. 21, 2009). [cited by applicant]
Conolly et al., “Weak Interactions Govern the Viscosity of Concentrated Antibody Solutions: High-Throughput Analysis Using the Diffusion Interaction Parameter” Biophysical Journal 103:69-78 (Jul. 2012). [cited by applicant]
Darden et al., “Particle mesh Ewald: An N log(N) method for Ewald sums in large systems” J. Chem. Phys. 98(12):10089-10092 (Jun. 15, 1993). [cited by applicant]
Du et al., “Hydrophobic Salts Markedly Diminish Viscosity of Concentrated Protein Solutions” Biotechnology and Bioengineering 108(3):632-636 (Mar. 2011). [cited by applicant]
Eisenberg et al., “Hydrophobic Moments and Protein Structure” Faraday Symp. Chem. Soc. 17:109-120 ( 1982). [cited by applicant]
Eisenhaber et al., “The Double Cubic Lattice Method: Efficient Approaches to Numerical Integration of Surface Area and Volume and to Dot Surface Contouring of Molecular Assemblies” Journal of Computational Chemistry 16(… [cited by applicant]
Gao et al., “In Silico Modeling of Nonspecific Binding to Human Liver Microsomes” Drug Metabolism & Disposition 36(10):2130-2135 ( 2008). [cited by applicant]
Hess et al., “GROMACS 4: Algorithms for Highly Efficient, Loas-Balanced, and Scalable Molecular Simulation” J. Chem. Theory Comput. 4:435-447 ( 2008). [cited by applicant]
Hess et al., “LINCS: A Linear Constraint Solver for Molecular Simulations” Journal of Computational Chemistry 18(12):1463-1472 ( 1997). [cited by applicant]
Hotzel et al., “A strategy for risk mitigation of antibodies with fast clearance” mAbs 4(6):753-760 ( 2012). [cited by applicant]
Igawa et al., “Engineering the variable region of therapeutic IgG antibodies” mAbs 3(3):243-252 ( 2011). [cited by applicant]
Igawa et al., “Reduced elimination of IgG antibodies by engineering the variable region” Protein Engineering, Design & Selection 23(5):385-392 ( 2010). [cited by applicant]
International Search Report ( Aug. 2015). [cited by applicant]
Iwao et al., “Oxidation of Arg-410 Promotes the Elimination of Human Serum Albumin” Biochimica et Biophysica Acta 1764:743-749 ( 2006). [cited by applicant]
Ji et al., “Methionine, Tryptophan, and Histidine Oxidation in a Model Protein, PTH: Mechanisms and Stabilization” Journal of Pharmaceutical Sciences 98(12):4485-4500 (Dec. 2009). [cited by applicant]
Jorgensen et al., “Comparison of simple potential functions for simulating liquid water” J. Chem. Phys. 79(2):926-935 (Jul. 15, 1983). [cited by applicant]
Jorgensen et al., “Development and Testing of the OPLS All-Atom Force Field on Conformational Energicts and Properties of Organic Liquids” J. Am. Chem. Soc. 118:11225-11236 ( 1996). [cited by applicant]
Kanai et al., “Reversible Self-Association of a Concentrated Monoclonal Antibody Solution Mediated by Fab-Fab Interaction that Impacts Solution Viscosity” Journal of Pharmaceutical Sciences 97(10):4219-4227 (Oct. 2008). [cited by applicant]
Kortkhonjia et al., “Solution Dynamics of Monoclonal Antibodies: Experimental and Computational Approach” Cell press 98(3 SUPPL 1):443a (Feb. 2010). [cited by applicant]
Lange et al., “Full correlation analysis of conformational protein dynamics” Proteins 70:1294-1312 (2008). [cited by applicant]
Lauer et al., “Developability Index: A Rapid In Silico Tool for the Screening of Antibody Aggregation Propensity” Journal of Pharmaceutical Sciences 10(1):112-114 (Jan. 2012). [cited by applicant]
Li et al., “Framework Selection Can Influence Pharmacokinetics of a Humanized Therapeutic Antibody Through Differences in Molecule Charge” mAbs 6(5):1255-1264 ( 2014). [cited by applicant]
Li et al., “Very Fast Empirical Prediction and Rationalization of Protein pKa Values” Proteins: Structure, Function, and Bioinformatics 61:704-721 ( 2005). [cited by applicant]
Liu et al., “Reversible Self-Association Increases the Viscosity of a Concentrated Monoclonal Antibody in Aqueous Soution” Journal of Pharmaceutical Sciences 94(9):1928-1940 (Sep. 2005). [cited by applicant]
Miyamoto et al., “SETTLE: An Analytical Version of the SHAKE and RATTLE Algorithm for Rigid Water Models” Jounal of Computational Chemisty 13(8):952-962 ( 1992). [cited by applicant]
Neergaard et al., “Viscosity of High Concentration Protein Formulations of Monoclonal Antibodies of the IgG1 and IgG4 Subclass—Prediction of Viscosity Through Protein-Protein Interaction Measurements” European Journal o… [cited by applicant]
Radkiewicz et al., “Neighboring Side Chain Effects on Asparaginyl and Aspartyl Degradation: An Ab Initio Study of the Relationship between Peptide Conformation and Backbone NH Acidity” J. Am. Chem. Soc. 123:3499-3506 ( … [cited by applicant]
Rojko et al., “Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes: Review and Case Studies” Toxicologic Pathology 42:725-764 ( 2014). [cited by applicant]
Sali et al., “Comparative Protein Modelling by Satisfaction of Spatial Restraints” J. Mo. Biol. 234:779-815 ( 1993). [cited by applicant]
Sharma et al., “In Silico Selection of Therapeutic Antibodies for Development: Viscotiy, Clearance, and Chemical Stability” PNAS 111(52):18601-18606 (Dec. 30, 2014). [cited by applicant]
Sharma et al., “Predictive tools toward screening monoclonal antibodies with optimal physicochemical properties” American Chemical Society, Abstracts of Papers 241 (Mar. 1, 2011). [cited by applicant]
Shire et al., “Challenges in the Development of High Protein Concentration Formulations” Journal of Pharmaceutical Sciences 93(6):1390-1402 (Jun. 2004). [cited by applicant]
Skogh et al., “Physicochemical Properties and Blood Clearance of Human Serum Albumin Conjugated to Different Extents with Dinitrophenyl Groups” Int. Archs Allergy appl. Immun. 70:238-244 ( 1983). [cited by applicant]
Sreedhara et al., “Characterization of the Isomerization Products of Aspartate Residues at Two Different Sites in a Monoclonal Antibody” Pharm. Res. 29:187-197 ( 2012). [cited by applicant]
Wakankar et al., “Aspartate Isomerization in the Complementarity-Determining Regions of Two Closely Related Monoclonal Antibodies” Biochemistry 46:1534-1544 ( 2007). [cited by applicant]
Wang et al., “Monoclonal Antibody Pharmacokinetics and Pharmacodynamics” Clinical Pharmacology & Therapeutics 84(5):548-558 (Nov. 2008). [cited by applicant]
Wu et al., “Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract” J. Mol. Biol. 368:652-665 ( 2007). [cited by applicant]
Xu et al., “Modigying the OPLS-AA Force Field to Improve Hydration Free Energies for Several Amino Acid Side Chains Using New Atomis Charges and an Off-Plane Charge for Aromatic Residues” J. Comput. Chem. 28:689-697 ( 2… [cited by applicant]
Yadav et al., “Establishing a Ling Between Amino Acid Sequences and Self-Associating and Viscoelastic Behavior of Two Closely Related Monoclonal Antibodes” Pharmaceutical Research 28:1750-1764 (2011). [cited by applicant]
Yadav et al., “Specific Interactions in High Concentration Antibody Solutions Resulting in High Viscosity” Journal of Pharmaceutical Sciences 99(3):1152-1168 (Mar. 2010). [cited by applicant]
Yadav et al., “The Influence of Charge Distribution on Self-Association and Viscosity Behavior of Monoclonal Antibody Solutions” Molecular Pharmaceutics 9:791-802 ( 2012). [cited by applicant]
Yi et al., “Isomerization of Asp-Asp Motif in Model Peptides and a Monoclonal Antibody Fab Fragment” Journal of Pharmaceutical Sciences 102(3):947-959 (Mar. 2013). [cited by applicant]
Yu et al., “Accurate Determination of Succimide Degradation Products Using High Fidelity Trypsin Digestion Peptide Map Analysis” Anal. Chem. 83:5912-5919 ( 2011). [cited by applicant]
Zheng et al., “Minipig as potential translatable model for monoclonal antibodypharmacokinetics after intravenous and subcutaneous administration” mAbs 4(2):243-255 (2012). [cited by applicant]
Henderson Hasselback Equation, Wikipedia, last updated Mar. 1, 2022, 4 pages. https://en.wikipedia.org/wiki/Henderson%E2%80%93Hasselbalch_equation, retrieved Mar. 1, 2022. [cited by applicant]
B. Helk, et. al., “PEGS Europe”, Final Agenda, Nov. 4-8, 2013, Lisbon, Portugal. [cited by applicant]
Eisenstein, Something New Under the Skin, 2011, 107-109, Nat Biotech 29. [cited by applicant]
Kindt et al. Kuby Immunology, 6th ed., 2007, p. 91, W.H. Freeman and Co. [cited by applicant]
Case, et al., Amber 11 Reference Manual, 2012 publication, University of California, San Francisco, all pages. [cited by applicant]